Pea Federico, Viale Pierluigi, Damiani Daniela, Pavan Federica, Cristini Francesco, Fanin Renato, Furlanut Mario
Institute of Clinical Pharmacology and Toxicology, DPMSC, University of Udine, P. le S. Maria della Misericordia 3, 33100 Udine, Italy.
Antimicrob Agents Chemother. 2005 Aug;49(8):3550-3. doi: 10.1128/AAC.49.8.3550-3553.2005.
The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.
对20例患有急性髓系白血病的发热性中性粒细胞减少患者，评估了每日6克头孢他啶持续静脉输注的药代动力学-药效学特征。从第2天起，头孢他啶的平均稳态浓度为40毫克/升，确保了最大的药效学暴露（该值接近针对铜绿假单胞菌的最低抑菌浓度断点的四到五倍）。然而，在整个研究期间记录到了较大的个体内和个体间药代动力学变异性。
